Brief: Ascletis Announces Promising Phase I Results In Australia For ASC47, Muscle-Preserving Weight Loss Drug for Obesity
07/11/2024 13:28
Nov 7 (Reuters) - Ascletis Pharma Inc 1672.HK :
* ASCLETIS ANNOUNCES PROMISING RESULTS FROM A PHASE I STUDY
IN
AUSTRALIA FOR FIRST-IN-CLASS MUSCLE-PRESERVING WEIGHT LOSS DRUG
CANDIDATE ASC47 FOR THE TREATMENT OF OBESITY
* ASCLETIS PHARMA INC - ASC47 SHOWS MUSCLE-PRESERVING WEIGHT
LOSS
IN PRE-CLINICAL STUDIES
Source text: ID:nPn5XBjnda
Further company coverage: 1672.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsAscletis hits 4-week high on initiating US Phase I study on obesity drug
Brief: Ascletis Pharma Initiates U.S. Phase I Study For ASC36 Oral Tablets For Obesity
Brief: Ascletis Pharma Inc. Says Board Of Directors Does Not Recommend Payment Of Any Dividend In Respect Of HY
China's Ascletis Pharma H1 net loss widens on higher R&D costs
Brief: Ascletis Announces First Participant Dosed In A Global Phase III Clinical Program Of Once-Daily Oral Small Molecule Glp-1 Receptor Agonist ASC30 For Chronic Weight Management